Fortress Biotech (NASDAQ:FBIO) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Fortress Biotech (NASDAQ:FBIO) in a report published on Thursday, Benzinga reports.

Other equities research analysts have also recently issued reports about the company. StockNews.com upgraded Fortress Biotech from a sell rating to a hold rating in a research note on Thursday. Roth Mkm reaffirmed a buy rating and issued a $10.00 price objective on shares of Fortress Biotech in a research note on Thursday, May 16th. Finally, Alliance Global Partners started coverage on Fortress Biotech in a research note on Tuesday, March 19th. They set a buy rating and a $5.00 target price for the company.

Fortress Biotech Stock Performance

NASDAQ:FBIO opened at $1.71 on Thursday. The company has a market cap of $34.06 million, a price-to-earnings ratio of -0.28 and a beta of 1.68. Fortress Biotech has a fifty-two week low of $1.24 and a fifty-two week high of $10.35. The company has a debt-to-equity ratio of 38.42, a quick ratio of 1.21 and a current ratio of 1.33. The stock has a fifty day moving average price of $1.81 and a 200-day moving average price of $2.06.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.00. Fortress Biotech had a negative net margin of 69.13% and a negative return on equity of 770.86%. The business had revenue of $13.03 million during the quarter, compared to analysts’ expectations of $14.33 million. As a group, equities analysts anticipate that Fortress Biotech will post -5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FBIO. Gladstone Institutional Advisory LLC bought a new position in Fortress Biotech in the 4th quarter valued at approximately $36,000. Virtu Financial LLC acquired a new position in Fortress Biotech in the 1st quarter valued at approximately $31,000. PFG Investments LLC acquired a new position in Fortress Biotech in the 1st quarter valued at approximately $33,000. Wealth Management Partners LLC bought a new position in shares of Fortress Biotech during the fourth quarter valued at $60,000. Finally, Choreo LLC acquired a new position in shares of Fortress Biotech during the fourth quarter worth $109,000. 96.51% of the stock is currently owned by institutional investors.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.